Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from NVO

These 2 Mega-Cap Stocks Could Be Even Cheaper Buys Than Nvidia on the Dip

The market appears to be underestimating just how much these two companies can grow.

Barchart

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

StockNews.com

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

Barchart

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

Barchart

What the Options Market Tells Us About Novo Nordisk

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades.

Benzinga

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 European Stocks to Buy as the Region Recovers

Recent data reveals that the eurozone economy has narrowly skirted a recession, showing lukewarm yet positive growth. With the EU and euro area expected to grow steadily over the next two years, investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Shell plc (SHEL) could be beneficial.…

StockNews.com

3 European Stocks to Buy as the Continent’s Economy Recovers

As Europe navigates a complex landscape of slowing inflation, stable employment, and modest GDP growth, it may be an opportune time for investors to consider investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Novartis (NVS), which are poised to capitalize on the continent’s recovery. Read on….

StockNews.com

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

StockNews.com

Will Novo Nordisk's (NVO) Q2 Earnings Reflect Its Market Potential?

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

StockNews.com

1 Huge New Reason This Diet Drug Stock is a Must-Own

The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult population was either overweight or obese. That's a massive market that just opened up for NVO.

Barchart

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

StockNews.com

3 Popular Pharma Stocks Worth Buying Now

The pharmaceutical industry is set for solid growth due to increased demand for effective treatments for regular and rare diseases, an aging population, and ongoing innovations in pharma technology. Hence, investors could consider buying quality pharmaceutical stocks such as Collegium Pharmaceutical (COLL), Novo Nordisk (NVO), and GSK (GSK). Read on.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

StockNews.com

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

Barchart

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Barchart

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

Barchart

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

StockNews.com

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

StockNews.com

3 Pharma Stocks for January 2024 Profits

The pharmaceutical industry is thriving, fueled by steady demand for drugs, cost-efficient alternative discoveries, and rapid technological innovations. Hence, fundamentally strong pharma stocks Novo Nordisk (NVO), Eton Pharmaceuticals (ETON), and Pacira BioSciences (PCRX) might be profitable buys now. Read on….

Barchart

3 Buy-Rated Healthcare Dividend Stocks for Income Investors

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

StockNews.com

3 Top-Rated Pharma Stocks Worth Including in Your November Portfolio

The pharmaceutical sector is booming with increasing global healthcare demands and technological progress. Hence, top-rated pharma stocks Dr. Reddy’s (RDY), Novo Nordisk (NVO), and AbbVie (ABBV) might be solid additions to one’s portfolio in November. Read more.

Barchart

3 'Strong Buy' Dividend Stocks That Are Beating the Market

Here are three top-rated dividend stocks that have outperformed the S&P 500 in the past month, despite a tough environment for equities.

1 … 3 4 5 6

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.